Search Weight Loss Topics:

Page 27«..1020..26272829..40..»

Home » Hgh » Page 27

COPENHAGEN, Denmark, March 25, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that the company will hold a conference call and live webcast onWednesday, April 1, 2020at4:30 p.m. Eastern Time(ET) to review its 2019 financial results and provide a business update.

Conference Call Details

A live webcast of the conference call will be available on the Investors and News section of theAscendis Pharmawebsite atwww.ascendispharma.com. A webcast replay will be available on this website shortly after conclusion of the event for 30 days.

About Ascendis Pharma A/S

Ascendis Pharmais applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.

Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus. The company continues to expand into additional therapeutic areas to address unmet patient needs.

Ascendis is headquartered in Copenhagen, Denmark, with offices in Heidelberg, Germany and Palo Alto, California.

For more information, please visit http://www.ascendispharma.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) our ability to apply our platform technology to build a leading, fully integrated biopharma company, (ii) our expectations regarding our ability to create new and potentially best-in-class therapies and (iii) our product pipeline and expansion into additional therapeutic areas. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development of TransCon hGH, TransCon PTH and TransCon CNP or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional funding, if needed, to support our business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, theU.S. Securities and Exchange Commission(SEC), including our Annual Report on Form 20-F for the year endedDecember 31, 2018, which we filed with theSEConApril 3, 2019. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments we may enter into or make. We do not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group. March 2020 Ascendis Pharma A/S.

Original post:
Ascendis Pharma A/S Announces Full Year 2019 Financial Results and Business Update Conference Call on April 1 - BioSpace

An in-depth market research study titled Global "Infrared Search and Track (IRST) Equipments Market" highlights several significant facets related to the Infrared Search and Track (IRST) Equipments market encompassing competitive landscape, segmentation analysis, and industry environment. The report details key statistics on the market position of the Infrared Search and Track (IRST) Equipments manufacturers is a proven valuable trajectory of guidelines and direction for companies and individuals interested in consolidating their position in the market. Realistic concepts of the market are explained lucidly in this report.

The segment also provides contact information, product specifications, company profiles, capacity, production value and market shares for the company. The report provides a basic overview of the Infrared Search and Track (IRST) Equipments industry, including its definition, applications and manufacturing technology. The report documents all global key industry players, coupled with their company profiles, size, production value, product specifications, capacity and 2020-2026 market shares occupied by each company are mentioned. The total market is further segmented by country, by the company and by application/type for the competitive landscape analysis.

Click Here To Access The Free Sample Report: https://www.syndicatemarketresearch.com/market-analysis/infrared-search-and-track-irst-equipments-market.html#sample

Major Market Players Covered In This Report: Lockheed Martin Corporation, Thales Group, Safran S.A., Rheinmetall AG., Leonardo S.p.A., Northrop Grumman Corporation, HGH Systemes Infrarouges SAS, Rheinmetall AG., Aselsan A.S, The Boeing Company

The key product type of Infrared Search and Track (IRST) Equipments market are: Airborne, Naval, Land

Infrared Search and Track (IRST) Equipments Market Outlook by Applications: Defense, Civil

Global Infrared Search and Track (IRST) Equipments Market Regional Trends Analysis

Regionally, the market is separated into North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. In which North America dominated the global Infrared Search and Track (IRST) Equipments market in 2019.

To Get This Report At Beneficial Rates, Inquiry Here: https://www.syndicatemarketresearch.com/inquiry/infrared-search-and-track-irst-equipments-market

The study offers important statistics on the Infrared Search and Track (IRST) Equipments market status of producers and offers valuable advice and direction for businesses and individuals interested in consolidating their position in the industry. The report then estimates the 2020-2026 market development trends of the Infrared Search and Track (IRST) Equipments industry. Analysis of current market dynamics, upstream raw materials, and downstream demand are also included in the report. The research was conducted for documenting leading growth status, segmentation, landscape analysis, developments, product types, and applications.

From the Infrared Search and Track (IRST) Equipments market research reports, the following points are available with detailed study at every point:

Production Analysis Initiation of this Infrared Search and Track (IRST) Equipments is analyzed based on top countries, types, and applications. Here, the report is expected to extensively focus on the price analysis of varied Infrared Search and Track (IRST) Equipments market key players.

Profit and Sales Evaluation Both earnings and sales are verified for various components of this international Infrared Search and Track (IRST) Equipments market. The reports focus on the price that plays a vital role in sales development for several regions.

Segments and Advantages In continuation of using earnings, this report studies the design and ingestion of its Infrared Search and Track (IRST) Equipments market. This report also highlights the difference between usage and supply, export, and import data.

Competition In this section, many global Infrared Search and Track (IRST) Equipments industry-top players have been studied based on their company profile, product portfolio, ability, price, cost, and revenue.

Other Analysis Besides the aforementioned information, demand, and supply scrutiny to the Infrared Search and Track (IRST) Equipments economy, contact information from leading producers, suppliers, and major consumers, can also be procured from the report.

Infrared Search and Track (IRST) Equipments Market by Region Segmentation:

North America Country (United States, Canada) Asia-Pacific Country (China, Japan, India, Korea, Australia) Europe Country (Germany, UK, France, Italy) Other Country (Middle East, Africa, GCC)

Global Infrared Search and Track (IRST) Equipments Market Study Report 2020 also provides brief details As:

1)Industry Overview2) Manufacturing Cost Structure Analysis3) Technical Data and Manufacturing Plants Analysis4) Global Market Overview5) Overall Regional Market Analysis6) Global Market Analysis by Type7) Global Market Analysis by Application8) Development Trend Analysis

To Know More About The Assumptions in This Market Report: https://www.syndicatemarketresearch.com/market-analysis/infrared-search-and-track-irst-equipments-market.html

Why Buy This Report?

The research report provides a complete analysis of the global Infrared Search and Track (IRST) Equipments market to help players create powerful growth strategies and achieve a strong position in the industry. The report presents a complete mapping of the market participants and the competitive landscape. Information on important sustainability strategies adopted by key companies along with their impact on market growth and competition has been provided in this report. All players can use the report to prepare themselves for facing impending market challenges and facing further competition in the global market.

The overview of crucial Infrared Search and Track (IRST) Equipments organizations concerning their assets, such as enhancements, cost, and client satisfaction discussed, is detailed in the analysis report.

About us:

Setting a strong foot in the industry with all planned and tactical approaches is surely not a cakewalk. You need loads of research, analysis, consider several factors, and above all, give your valuable time to the entire process. This is where Syndicate Market Research kicks in as a support system for our clients.

Contact Us:

Syndicate Market Research244 Fifth Avenue, Suite N202New York, 10001, United States+1 347 535 0815 | Email ID:sales@syndicatemarketresearch.comwebsite:www.syndicatemarketresearch.com

Sorry! The Author has not filled his profile.

Read more from the original source:
Global Infrared Search and Track (IRST) Equipments Market 2020 -2026 Trends Analysis | Key Players Lockheed Martin Corporation, Thales Group, Safran...

The global Infrared Search and Track (IRST) system market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Researchs latest publication, titled global Infrared Search and Track (IRST) system market, offers an insightful take on the drivers and restraints present in the market. It assesses the historical data pertaining to the global Infrared Search and Track (IRST) system market and compares it to the current market trends to give the readers a detailed analysis of the trajectory of the market. A team subject-matter experts have provided the readers a qualitative and quantitative data about the market and the various elements associated with it.

Get the Sample of this [emailprotected]https://www.qyresearch.com/sample-form/form/1589238/global-infrared-search-and-track-irst-system-market

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Infrared Search and Track (IRST) system market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

Market Segments Covered:

Key Players:Aselsan, HGH Systmes Infrarouges, Leonardo, Lockheed Martin Corporation, Northrop Grumman Corporation, Rheinmetall, Safran, Thales Group, Tonbo Imaging Private Limited

Segment by Types:CivilGrade, MilitaryGrade

Segment by Applications:Airborne, Naval, Land, Others

Regions Covered in the Global Infrared Search and Track (IRST) system Market:

The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Highlights of the Report Accurate market size and CAGR forecasts for the period 2019-2025 Identification and in-depth assessment of growth opportunities in key segments and regions Detailed company profiling of top players of the global Infrared Search and Track (IRST) system market Exhaustive research on innovation and other trends of the global Infrared Search and Track (IRST) system market Reliable industry value chain and supply chain analysis Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

The scope of the Report:

The report segments the global Infrared Search and Track (IRST) system market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritties of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also address political scenarios that are expected to impact the market in both small and big ways.The report on the global Infrared Search and Track (IRST) system market examines changing regulatory scenario to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Get Customized Report in your Inbox within 24 hours @https://www.qyresearch.com/customize-request/form/1589238/global-infrared-search-and-track-irst-system-market

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Infrared Search and Track (IRST) system market

Chapter 2: Evaluating the leading manufacturers of the global Infrared Search and Track (IRST) system market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales

Chapter 4: Presenting global Infrared Search and Track (IRST) system market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9 : To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions

About Us:QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Originally posted here:
Forecast Report on Infrared Search and Track (IRST) system Market Analysis and Consumption Overview 2020-2026 | Aselsan, HGH Systmes Infrarouges,...

To the annoyance of some shareholders, Heartland Group Holdings (NZSE:HGH) shares are down a considerable 34% in the last month. The recent drop has obliterated the annual return, with the share price now down 20% over that longer period.

Assuming nothing else has changed, a lower share price makes a stock more attractive to potential buyers. In the long term, share prices tend to follow earnings per share, but in the short term prices bounce around in response to short term factors (which are not always obvious). The implication here is that long term investors have an opportunity when expectations of a company are too low. Perhaps the simplest way to get a read on investors' expectations of a business is to look at its Price to Earnings Ratio (PE Ratio). Investors have optimistic expectations of companies with higher P/E ratios, compared to companies with lower P/E ratios.

Check out our latest analysis for Heartland Group Holdings

Heartland Group Holdings's P/E of 10.01 indicates some degree of optimism towards the stock. You can see in the image below that the average P/E (8.5) for companies in the banks industry is lower than Heartland Group Holdings's P/E.

NZSE:HGH Price Estimation Relative to Market, March 16th 2020

Heartland Group Holdings's P/E tells us that market participants think the company will perform better than its industry peers, going forward. Shareholders are clearly optimistic, but the future is always uncertain. So further research is always essential. I often monitor director buying and selling.

Probably the most important factor in determining what P/E a company trades on is the earnings growth. That's because companies that grow earnings per share quickly will rapidly increase the 'E' in the equation. Therefore, even if you pay a high multiple of earnings now, that multiple will become lower in the future. And as that P/E ratio drops, the company will look cheap, unless its share price increases.

Notably, Heartland Group Holdings grew EPS by a whopping 27% in the last year. And it has bolstered its earnings per share by 4.6% per year over the last five years. With that performance, I would expect it to have an above average P/E ratio.

The 'Price' in P/E reflects the market capitalization of the company. In other words, it does not consider any debt or cash that the company may have on the balance sheet. The exact same company would hypothetically deserve a higher P/E ratio if it had a strong balance sheet, than if it had a weak one with lots of debt, because a cashed up company can spend on growth.

Such spending might be good or bad, overall, but the key point here is that you need to look at debt to understand the P/E ratio in context.

Net debt totals a substantial 133% of Heartland Group Holdings's market cap. This level of debt justifies a relatively low P/E, so remain cognizant of the debt, if you're comparing it to other stocks.

Heartland Group Holdings trades on a P/E ratio of 10.0, which is below the NZ market average of 17.0. The company has a meaningful amount of debt on the balance sheet, but that should not eclipse the solid earnings growth. If it continues to grow, then the current low P/E may prove to be unjustified. Given Heartland Group Holdings's P/E ratio has declined from 15.2 to 10.0 in the last month, we know for sure that the market is significantly less confident about the business today, than it was back then. For those who prefer to invest with the flow of momentum, that might be a bad sign, but for a contrarian, it may signal opportunity.

Story continues

Investors have an opportunity when market expectations about a stock are wrong. If the reality for a company is not as bad as the P/E ratio indicates, then the share price should increase as the market realizes this. So this free visual report on analyst forecasts could hold the key to an excellent investment decision.

Of course, you might find a fantastic investment by looking at a few good candidates. So take a peek at this free list of companies with modest (or no) debt, trading on a P/E below 20.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

More:
How Does Heartland Group Holdings's (NZSE:HGH) P/E Compare To Its Industry, After The Share Price Drop? - Yahoo Finance

Seven teams graced the No. 1 spot in the AP college basketball rankings this season.

That's tied for the most since 1983.

It's a testament to just how topsy-turvy college basketball was this season. And, most of all, it served as a barometer for just how good -- no, just how great -- March Madness would have been. Should have been.

During the glorious regular season, we saw Evansville take down No. 1 Kentucky as a 24.5 point underdog ... at Rupp Arena. We saw Stephen F. Austin stun No. 1 Duke at the buzzer as a 28 point underdog ... inside Cameron Indoor. Oh, and did I mention Evansville took down Kentucky? That's certainly worth mentioning in this space here.

This was going to be the year of the wide-open title race before the NCAA championships were canceled this week over fears of the coronavirus pandemic. The season was predictable only in that everything was wholly unpredictable. And in March Madness -- where upsets are the norm and volatility is a staple -- we were going to have it in spades. We were expecting it to be March Madness on steroids, but if those steroids had also been juiced with HGH.

Now we'll never know what might've happened.

Simulate the season on a computer like the SportsLine folks did, and Dayton wins it all. Use statistical metrics like KenPom or Bart Torvik, and Kansas from top to bottom is considered the best team. Draw a name out of a hat, and well, who the heck knows?

The latter is the measure I choose to believe would have been the most accurate in predicting who might win it all this season, too. You could make a legitimate case for 15-plus teams to be considered real title threats in 2020.

San Diego State had its best shot to win it all in years after posting a 30-2 record. Villanova could've won its third title since 2016. Baylor's dream season could've turned into a fairytale ending. Dayton, Maryland, Michigan State, Seton Hall, Duke, Kentucky -- the list goes on. Each one of those programs had real mettle to play deep into March, perhaps into early April.

There's absolutely no sugarcoating it: it stinks for everyone.

But there's also some fun hypotheticals that come with the cancellation of the season now that uncertainty is the only certain in what was, frankly, one of the most fun and frenzied college hoops seasons the last decade. There's excitement in the unknown. You can make your own assessment and judge it your own way. If you thought Dayton was the most potent team in the sport, then hey, you own that. If you thought Kansas' duo of Devon Dotson and Udoka Azubuike was a legitimate enough tandem to carry KU to the crown, then maybe that's the team that sticks with you, the team you'll always ride for when we reflect on the chaos of 2020. Maybe you bought in to Seton Hall or Kentucky and thought they had the best chance to cut down nets.

The fun part is that no matter how you view it, you're not wrong. It's the ultimate sports what-if with no real answer. We now have a bar topic to debate for the rest of our lives. (Kansas, for my money, was my pick. Buy me a beer and convince me otherwise.)

And hey, let's face it: The real fun of college basketball is that the best team in college basketball every season doesn't always win the national championship. The 2014-15 Kentucky team went 38-0 ... then lost in the Final Four to Wisconsin. The 1996-1997 Kansas team led by Paul Pierce and Raef LaFrentz -- which went 34-2 -- fell in the Sweet Sixteen that year. The Fab Five's second iteration, in 1992-1993, went 31-5 and eventually fell -- in part because of the infamous Chris Webber timeout -- to North Carolina in the title game. There's a randomness to single-elimination tournaments that consistently invites chaos.

And that is why we love March.

Now the only chaos is off the court, leaving us to wonder what might have transpired on it. We'll never know. But the fun of the unknown is enough to keep us coming back.

Here is the original post:
Simulation Sunday: Projections of the 2020 NCAA Tournament show we could have had a wild March Madness - CBS Sports

(Alas, SLU did not make the mythical bracket, so the Billikens did not get to play any pretend games. With time on their hands, perhaps the SportsLine team will run an NIT simulation.)

In the St. Louis portion of this virtual event, with the games played at Enterprise Center: Wisconsin beat East Tennessee 71-65, Kentucky beat Vermont 74-64, Michigan beat Utah State 74-69 and Creighton defeated Ohio Valley Conference power Belmont 84-70. Then Kentucky beat Wisconsin 69-68 and Creighton beat Michigan 77-74.

Here is what folks have been writing about college basketball:

Kyle Boone, CBSSports.com: This was going to be the year of the wide-open title race before the NCAA championships were canceled this week over fears of the coronavirus pandemic. The season was predictable only in that everything was wholly unpredictable. And in March Madness -- where upsets are the norm and volatility is a staple -- we were going to have it in spades. We were expecting it to be March Madness on steroids, but if those steroids had also been juiced with HGH. Now we'll never know what might've happened. Simulate the season on a computer like the SportsLine folks did, and Dayton wins it all. Use statistical metrics like KenPom or Bart Torvik, and Kansas from top to bottom is considered the best team. Draw a name out of a hat, and well, who the heck knows? The latter is the measure I choose to believe would have been the most accurate in predicting who might win it all this season, too. You could make a legitimate case for 15-plus teams to be considered real title threats in 2020. San Diego State had its best shot to win it all in years after posting a 30-2 record. Villanova could've won its third title since 2016. Baylor's dream season could've turned into a fairytale ending. Dayton, Maryland, Michigan State, Seton Hall, Duke, Kentucky -- the list goes on. Each one of those programs had real mettle to play deep into March, perhaps into early April.

Go here to see the original:
Tipsheet: Dayton wins NCAA basketball title on Simulation Sunday - STLtoday.com

Seven different teams graced the No. 1 spot in the AP college basketball rankings this season.

That's tied for the most since 1983.

It's a testament to just how topsy-turvy college basketball was this season. And, most of all, it served as a baromoter for just how good -- no, just how great -- March Madness would have been. Should have been.

During the glorious regular season, we saw Evansville take down No. 1 Kentucky as 24.5 point underdogs ... at Rupp Arena. We saw Stephen F. Austin stun No. 1 Duke at the buzzer as 28 point underdogs ... inside Cameron Indoor. Oh, and did I mention Evansville took down Kentucky? That's certainly worth mentioning in this space here.

This was going to be the year of the wide-open title race before the NCAA championships were canceled this week over fears of the coronavirus pandemic. The season was predictable only in that everything was wholly unpredictable. And in March Madness -- where upsets are the norm and volatility is a staple -- we were going to have it in spades. We were expecting it to be March Madness on steroids, but if those steroids had also been juiced with HGH.

Now we'll never know what might've happened.

Simulate the season on a computer like the SportsLine folks did, and Dayton wins it all. Use statistical metrics like KenPom or Bart Torvik, and Kansas from top to bottom is considered the best team. Draw a name out of a hat, and well, who the heck knows?

The latter is the measure I choose to believe would have been the most accurate in predicting who might win it all this season, too. You could make a legitimate case for 15-plus teams to be considered real title threat in 2020.

San Diego State had its best shot to win it all in years after posting a 30-2 record. Villanova could've won its third title since 2016. Baylor's dream season could've turned into a fairytale ending. Dayton, Maryland, Michigan State, Seton Hall, Duke, Kentucky -- the list goes on. Each one of those programs had real mettle to play deep into March, perhaps into early April.

There's absolutely no sugarcoating it: it stinks for everyone.

But there's also some fun hypotheticals that come with the cancellation of the season now that uncertainty is the only certain in what was, frankly, one of the most fun and frenzied college hoops seasons the last decade. There's excitement in the unknown. You can make your own assessment and judge it your own way. If you thought Dayton was the most potent team in the sport, then hey, you own that. If you thought Kansas' duo of Devon Dotson and Udoka Azubuike was a legitimate-enough tandem to carry KU to the crown, then maybe that's the team that sticks with you, the team you'll always ride for when we reflect on the chaos of 2020. Maybe you bought in to Seton Hall or Kentucky and thought they had the best chance to cut down nets.

The fun part is that no matter how you view it, you're not wrong. It's the ultimate sports what-if with no real answer. We now have a bar topic to debate for the rest of our lives. (Kansas, for my money, was my pick. Buy me a beer and convince me otherwise.)

And hey, let's face it: the real fun of college basketball is that the best team in college basketball every season doesn't always win the national championship. 2014-15 Kentucky went 38-0 ... then lost in the Final Four to Wisconsin. The 1996-1997 Kansas team led by Paul Pierce and Raef LaFrentz -- which went 34-2 -- fell in the Sweet 16 that year. The Fab Five's second iteration, in 1992-1993, went 31-5 and eventually fell -- in part because of the infamous Chris Webber timeout -- to North Carolina in the title game. There's a randomness to single-elimination tournaments that consistently invites chaos.

And that is why we love March.

Now the only chaos is off the court, leaving us to wonder what might have transpired on it. We'll never know. But the fun of the unknown is enough to keep us coming back.

Go here to see the original:
Simulation Sunday: Projections of the 2020 NCAA Tournament shows we could have had a wild March Madness - CBS Sports

The Mega Washer Toss Fundraiser which was held at the Hawkesbury Legion on February 22, 2020 has raised $2,320 for the Hawkesbury and District General Hospital (HGH) Foundation. The event, which was sold out with 65 participants, was organized by Legion members Yves Paquette and Yvon Doiron, in support of HGHs cardiology department.

The event itself raised a total of $1,320 to which the Hawkesbury Legion generously contributed an additional $1,000. The cheque was presented at the Hawkesbury Legion on March 3, 2020 as reflected in the photo. Present and included in the photo were (from left to right): Yvon Doiron (Hawkesbury Legion member), Pierre-Luc Byham (Executive Director, HGH Foundation), Erin Tabakman (Donor Relations Officer, HGH Foundation), and Yves Paquette (Hawkesbury Legion member).

The HGH Foundation would like to express its sincere thanks to Mr. Paquette and to Mr. Doiron for their organization of this event as well as to their sponsors and the Hawkesbury Legion Branch 472 for their contribution and many years of support.

The Hawkesbury and District General Hospital (HGH) Foundation

The HGH Foundations mission is to raise funds in order to improve the care and services offered to the community by the Hawkesbury and District General Hospital.

The HGH Foundations new campaign, Theres No Place Like Home, will focus on enhancing specialized services in orthopedic surgery, ophthalmology, urology and nuclear medicine. This focus reflects the most pressing and increasing needs of our local population. Community support will continue to help ensure that new medical equipment is available to meet our regions healthcare needs and to make the most of HGHs recent redevelopment and expansion.

Read the original:
Profits from Mega Washer Toss fundraiser will benefit HGH's cardiology department - The Review Newspaper

Human Growth Hormone Therapy in Jersey City

Jersey City natives now have an invaluable resource to their health with a nationally acclaimed leader in healthcare services in HealthGAINS. Patients of all ages can experience the benefits of elite hormone therapy services. Our hormones are the messengers of our bodies that trigger every important process that our body performs. When our bodies dont have a sufficient supply of hormones, we dont feel the same. We become weaker, more irritable, less focused and more vulnerable to illnesses and injuries. HGH therapy is a vitally important procedure that replenishes patients growth hormone levels and renews their energy, strength and overall health and wellness. If you notice any of the signs of an HGH deficiency (signs of aging), contact your local Jersey City HealthGAINS clinic immediately.

For a free consultation call (305) 912-8828

The human growth hormone is responsible for some of the most important processes in the body. They produce and repair every cell in our bodies; they regulate our libido; control our metabolism; are responsible for our energy levels; boost immune and cardiovascular health; produce our bone and muscle mass; maintain healthy blood pressure and cholesterol levels and many other important processes. Without a sufficient supply of growth hormones, our bodies will experience life-altering side effects.

Hormone Therapy Specialist Near Me (305) 912-8828

When we are young and healthy, we are full of the vital hormones our bodies need to keep us strong and vital. As we age or through certain injuries and conditions, we slow down our production of HGH. This can cause a number of side effects including:

Click to contact our specialist today

Complete a Free Consultation form now

One of the first treatment applications for growth hormone therapy was to treat the symptoms of menopause. Not only can women experience the rejuvenating benefits of routine HGH therapy, but for women going through the life-changing event that is menopause, HGH therapy can minimize these symptoms and help women make the most of their lives no matter phase they are in.

Men can experience erectile dysfunction from low levels of HGH. For these men, growth hormone treatments have the ability to reverse these symptoms and return these men to their full sexual health.

HGH treatments focus on two methods of relief from growth hormone deficiencies 1) Injections of growth hormone-releasing peptides and 2) Direct injections of HGH into the patients body. Both treatment methods are extremely effective at relieving the symptoms of HGH imbalances and either directly or indirectly add the necessary growth hormones into the patients body to correct their deficiency.

At HealthGAINS, we specialize in bioidentical HGH treatments. This means that the hormones that we use for our growth hormone treatments are derived from nature (yams, soy, pigs, horses) and are exact molecular matches to human hormones. This ensures that patients will have the safest and most effective hormone therapy procedure that is available.

It is rare for patients of certified HGH doctors to experience adverse effects. At HealthGAINS, we adhere to the strictest and safest of measures for treating growth hormone deficient patients. In this way, we ensure that our patients have as little risks as possible when receiving HGH therapy.

Most cases of side effects from HGH treatments are from athletes or other people taking illegitimate forms of HGH for athletic or other physical gains. This excessive use and often abuse of HGH can lead to swelling, pain in the recipients joints, muscles and nerves, carpal tunnel syndrome, high cholesterol, and numbness.

Our HGH therapy consultations focus on three main goals 1) Diagnosing the patients hormone deficiency 2) Informing the patient of their treatment options and how each procedure will benefit their needs 3) Prescribing the precise dose of HGH to sufficiently treat the patients imbalance.

We will greet the patient and go over their medical history as well as listen to their symptoms. The doctor will then administer a blood test to analyze the patients hormone levels. With the analysis of the patients hormone levels, the doctor will then advise the patient as to which treatment option or options will best treat their unique case of HGH deficiency. Based on the patients wants, the doctor will prescribe the necessary dose of HGH that will treat the patients symptoms.

I have been battling my older age for years. I was a college athlete, so Im not used to feeling limited physically. However, when I reached a certain age, no amount of exercise seemed to keep my body in the shape I wanted it to be in. It got to the point where I figured there was something else going on that was making me feel so sluggish and weak. Sure enough after my consultation at HealthGAINS in Jersey City, my HGH doctor informed that I had declining growth hormone levels and it was changing the way my body produced and maintained my muscle mass. After a few weeks from my treatment, I was feeling like I was in college again with how I was lifting and running. Ebony R., 43

I had a severe growth hormone deficiency after a bad car wreck that injured my head. Doctors told me that if I didnt get it treated that it would completely diminish my ability to think properly, manage my weight, produce muscle mass, regulate my immune and heart health and many other life changing symptoms. I chose HealthGAINS because of their reputation in not just Jersey City but around the U.S. It required a series of HGH treatments over the course of a few months but I can say that after a year from my accident, I am confident that I can reclaim all of my old functions if not even healthier than before. Jeremy C., 32

A couple of my friends has received HGH therapy during menopause and they had amazing things to say. When I first started to experience the change, I knew HGH treatments was what I wanted to do to manage my symptoms. I never had to go through any of the life-altering changes that most women experience during their menopause. Jackie Y., 55

We dont have a recommended age for HGH treatments, because at HealthGAINS we ensure that all of our HGH treatments are safe for patients of all ages. So while most of our patients are in their 40s and 50s, we have treated everyone from children with development issues to elderly patients well into their 90s looking to manage their symptoms of aging.

Our HGH treatments cost $600 to $2,500 depending on the severity of your deficiency. This is why it important to schedule a consultation so that you can have your HGH levels tested to establish a legitimate quote for your unique treatment.

Yes! One of the major functions of growth hormones is to maintain our bodys metabolism. When we are deficient in HGH, our metabolism suffers and is less effective at breaking down the food that we eat. HGH therapy replenishes patients low HGH levels and in turn, improves their metabolisms to boost weight loss.

As HGH therapy is a whole-body treatment, it can take between 2 and 8 weeks for patients to feel the full effects of their treatment.

Yes. HGH is a controlled substance so it is illegal to use HGH without a prescription from a sanctioned doctor for a recognized medical condition, such as low growth hormone levels.

When you choose HGH therapy, you are choosing to take charge of your life and your age. Most of the effects of aging are simply the result of low hormone levels. HGH therapy gives patients of all ages the ability to live their happiest and healthiest lives. Call HealthGAINS at (866) 540-3555 to schedule your HGH therapy consultation today.

Offering HGH therapy treatments for New Jersey locals with declining levels of growth hormones in Jersey City and its surrounding areas of: New York City, Newark, Linden, Clifton, Montclair, Summit, Woodbridge Township, Perth Amboy, Plainfield, Edison, Livingston, Paterson, Union and Elizabeth.

Call or text (305) 912-8828 or complete a Free Consultation Form

See the original post here:
Human Growth Hormone (HGH) Therapy in Jersey City, NJ ...

Munzir Obaid,1 Ayman El-Menyar,2,3 Mohammad Asim,2 Hassan Al-Thani1

1Department of Surgery, Hamad General Hospital (HGH), Doha, Qatar; 2Department of Surgery, Clinical Research, Trauma and Vascular Surgery Section, HGH, Doha, Qatar; 3Department of Clinical Medicine, Weill Cornell Medical School, Doha, Qatar

Correspondence: Ayman El-MenyarWeill Cornell Medical College, Consultant Clinical Research, Trauma Surgery, Hamad General Hospital, Doha, QatarTel +974 44394029Fax +974 44394031Email aymanco65@yahoo.com

Background: We aimed to study theprevalence and outcomes of thrombophilia in acute pulmonary embolism.Methods: A retrospective observational study was conducted to include patients with a radiologically confirmed diagnosis of PE screened for thrombophilia from May 2011 to February 2015. Data included patients demographics; clinical presentation, risk factors, laboratory investigations, management, and outcome were analyzed and compared in patients with and without thrombophilia.Results: A total of 227 cases of PE were included in the study, of which 108 (47.6%) had thrombophilia. The most frequent coagulopathic abnormality included deficiency of protein S, protein C, andantithrombin III and hyperhomocysteinemia. Only seven out of 79 patients werefound to have factor V Leiden. PE patients diagnosed with thrombophilia were 10 years younger in age and peaked in the age range 30 39 years. Prior history of DVT (p=0.001) and PE (p=0.001) were the main significant risk factors in thethrombophilia group. The frequency of different risk categories of clinical probability scores did not differ significantly among those with and without thrombophilia. Pulmonary hypertension was a common complication in thethrombophilia group (P=0.009). Medications used included warfarin (74.7%), enoxaparin (73.9%), and heparin (55.4%). The overall mortality rate was 8.4%, and was non-significantly higher in the non-thrombophilia group.Conclusion: Deficiencies of protein S, protein C, and antithrombin III are the leading causes of thrombophilic defects. Patients with hereditary thrombophilia are at increased risk of acute PE, particularly among young individuals. Therefore, early detection of thrombophilic defects together with other unprovoked risk factors could reduce the risk of recurrent VTE.

Keywords: pulmonary embolism, thrombophilia, risk factors, thromboembolism, outcome

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continue reading here:
Prevalence and Outcomes of Thrombophilia in Patients with Acute Pulmon | VHRM - Dove Medical Press

Page 27«..1020..26272829..40..»

Home » Hgh » Page 27